PHINDER Trial Update: How Earlier Pulmonary Hypertension Screening Could Shape United Therapeutics’ Market
United Therapeutics Corp. (UTHR) announced an update on their ongoing clinical study.
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
United Therapeutics (UTHR) is backing a study called “Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER).” The goal is to test simple ways to spot pulmonary hypertension earlier in people with interstitial lung disease, which could help doctors act sooner and expand the treatable patient pool.
The study uses a procedure known as right heart catheterization, or RHC. This test directly measures blood flow and pressure in the lungs and heart, and it is used here to confirm how well different screening tools pick up early disease.
PHINDER is an observational study, so doctors only observe and measure rather than assign drugs. All patients enter a single cohort and receive the RHC, and researchers then compare what they see in this test to simpler screening checks used in clinics.
The study was first submitted on March 1, 2023, marking the start of formal enrollment and setup. The latest update was filed on May 26, 2026, which signals that data tracking and reporting are active even though top-line results are not yet posted.
The trial is listed as completed, meaning patient visits and procedures are done and data analysis is underway. Primary and final completion dates have not been posted yet, so investors should watch for a later data readout that could clarify how soon any new screening approach might reach daily practice.
For investors, the key issue is whether earlier detection can expand the market for pulmonary hypertension drugs made by United Therapeutics. If the study shows that more patients can be diagnosed sooner, it could support higher long-term demand for the company’s therapies.
This update also matters within the broader pulmonary hypertension space, where firms like Johnson & Johnson and Merck track new ways to find patients earlier. A positive data signal could lift sentiment around UTHR by suggesting a larger treated population, while weak or unclear results may limit near-term stock reaction.
Because the study is observational and procedure-based, it does not create direct drug approval risk but instead informs guidelines and referral patterns. That makes the potential stock impact more gradual, tied to uptake of new screening tools rather than a single binary catalyst.
Overall, PHINDER adds to United Therapeutics’ strategy of deepening its role in pulmonary hypertension care, not just through drugs but also through diagnosis. The study is completed and recently updated, and investors can find further details on the ClinicalTrials portal.
To learn more about UTHR’s potential, visit the United Therapeutics Corp. drug pipeline page.
